To evaluate the long-term outcomes of sentinel lymph node biopsy (SLNB) for head and neck cutaneous melanoma (HNCM).
Study Design
Retrospective cohort study.
Setting
Tertiary academic medical center.
Subjects and Methods
Longitudinal review of a 356-patient cohort with HNCM undergoing SLNB from 1997 to 2007.
Results
Descriptive characteristics included the following: age, 53.5 ± 19 years (mean ± SD); sex, 26.8% female; median follow-up, 4.9 years; and Breslow depth, 2.52 ± 1.87 mm. Overall, 75 (21.1%) patients had a positive SLNB. Among patients undergoing completion lymph node dissection following positive SLNB, 20 (27.4%) had at least 1 additional positive nonsentinel lymph node. Eighteen patients with local control and negative SLNB developed regional disease, indicating a false omission rate of 6.4%, including 10 recurrences in previously unsampled basins. Ten-year overall survival (OS) and melanoma-specific survival (MSS) were significantly greater in the negative sentinel lymph node (SLN) cohort (OS, 61% [95% CI, 0.549-0.677]; MSS, 81.9% [95% CI, 0.769-0.873]) than the positive SLN cohort (OS, 31% [95% CI, 0.162-0.677]; MSS, 60.3% [95% CI, 0.464-0.785]) and positive SLN/positive nonsentinel lymph node cohort (OS, 8.4% [95% CI, 0.015-0.474]; MSS, 9.6% [95% CI, 0.017-0.536]). OS was significantly associated with SLN positivity (hazard ratio [HR], 2.39; P < .01), immunosuppression (HR, 2.37; P < .01), angiolymphatic invasion (HR, 1.91; P < .01), and ulceration (HR, 1.86; P < .01). SLN positivity (HR, 3.13; P < .01), angiolymphatic invasion (HR, 3.19; P < .01), and number of mitoses (P = .0002) were significantly associated with MSS. Immunosuppression (HR, 3.01; P < .01) and SLN status (HR, 2.84; P < .01) were associated with recurrence-free survival, and immunosuppression was the only factor significantly associated with regional recurrence (HR, 6.59; P < .01).
Conclusions
Long-term follow up indicates that SLNB showcases durable accuracy, safety, and prognostic importance for cutaneous HNCM.
MortonDLWenDRWongJH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
2.
MortonDLThompsonJFCochranAJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-1317.
3.
JonesELJonesTSPearlmanNW, et al. Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg. 2013;148:456-461.
4.
SchmalbachCEBradfordCR. Is sentinel lymph node biopsy the standard of care for cutaneous head and neck melanoma?Laryngoscope. 2015;125:153-160.
5.
McMastersKMReintgenDSRossMI, et al. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed?Ann Surg Oncol. 2001;8:192-197.
6.
MortonDLThompsonJFCochranAJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599-609.
7.
GershenwaldJEThompsonWMansfieldPF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976-983.
8.
MortonDLWanekLNizzeJAElashoffRMWongJH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes: analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg. 1991;214:491-499.
9.
ErmanABCollarRMGriffithKA, et al. Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. Cancer. 2012;118:1040-1047.
10.
LeongSPAccorttNAEssnerR, et al. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch Otolaryngol Head Neck Surg. 2006;132:370-373.
11.
StoffelsIBoyCPoppelT, et al. Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease-free survival in melanoma. JAMA. 2012;308:1007-1014.
12.
O’BrienCJUrenRFThompsonJF, et al. Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy. Am J Surg. 1995;170:461-466.
13.
WillisAIRidgeJA. Discordant lymphatic drainage patterns revealed by serial lymphoscintigraphy in cutaneous head and neck malignancies. Head Neck. 2007;29:979-985.
14.
CarlsonGWPageAJCohenC, et al. Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg. 2008;248:378-386.
15.
SchmalbachCENussenbaumBReesRSSchwartzJJohnsonTMBradfordCR. Reliability of sentinel lymph node mapping with biopsy for head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg. 2003;129:61-65.
16.
KavehAHSeminaraNMBarnesMA, et al. Aberrant lymphatic drainage and risk for melanoma recurrence after negative sentinel node biopsy in middle-aged and older men. Head Neck. 2016;38(suppl 1):E754-E760.
17.
ChaoCWongSLEdwardsMJ, et al. Sentinel lymph node biopsy for head and neck melanomas. Ann Surg Oncol. 2003;10:21-26.
18.
CarlsonGWMurrayDRLylesRHHestleyACohenC. Sentinel lymph node biopsy in the management of cutaneous head and neck melanoma. Plast Reconstr Surg. 2005;115:721-728.
19.
SaltmanBEGanlyIPatelSG, et al. Prognostic implication of sentinel lymph node biopsy in cutaneous head and neck melanoma. Head Neck. 2010;32:1686-1692.
20.
Gomez-RiveraFSantillanAMcMurpheyAB, et al. Sentinel node biopsy in patients with cutaneous melanoma of the head and neck: recurrence and survival study. Head Neck. 2008;30:1284-1294.
21.
HanksJEYalamanchiPYKovatchKJAliSA, et al. Cranial nerve outcomes in regionally recurrent head and neck melanoma after sentinel lymph node biopsy [published online August23, 2019]. Laryngoscope. doi:10.1002/lary.28243
22.
FariesMBThompsonJFCochranAJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211-2222.
23.
LeiterUStadlerRMauchC, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:757-767.
24.
RossMI. Counterpoint: surgical management of lymph node basin in sentinel lymph node-positive melanoma. Oncology. 2016;30:891, 893-895.
25.
SarnaikAAZagerJSSondakVK. Point: surgical management of lymph node basin in sentinel lymph node–positive melanoma. Oncology. 2016;30:891-892, 895.
26.
RoskoAJVankoeveringKKMcLeanSAJohnsonTMMoyerJS. Contemporary management of early-stage melanoma: a systematic review. JAMA Facial Plast Surg. 2017;19:232-238.
27.
BalchCMSoongSJGershenwaldJE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
28.
BalchCMBuzaidACSoongSJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
29.
CascinelliNBelliFSantinamiM, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol. 2000;7:469-474.
30.
EvrardDRoutierEMateusC, et al. Sentinel lymph node biopsy in cutaneous head and neck melanoma. Eur Arch Otorhinolaryngol. 2018;275:1271-1279.
31.
SperrySMCharltonMEPagedarNA. Association of sentinel lymph node biopsy with survival for head and neck melanoma: survival analysis using the SEER database. JAMA Otolaryngol Head Neck Surg. 2014;140:1101-1109.
32.
ParrettBMKashani-SabetMSinger, et al. Long-term prognosis and significance of the sentinel lymph node in head and neck melanoma. Otolaryngol Head Neck Surg. 2012;147:699-706.
33.
TeltzrowTOsingaJSchwipperV. Reliability of sentinel lymph-node extirpation as a diagnostic method for malignant melanoma of the head and neck region. Int J Oral Maxillofac Surg. 2007;36:481-487.
34.
de WiltJHThompsonJFUrenRF, et al. Correlation between preoperative lymphoscintigraphy and metastatic nodal disease sites in 362 patients with cutaneous melanomas of the head and neck. Ann Surg. 2004;239:544-552.
35.
DotingEHde VriesMPlukkerJT, et al. Does sentinel lymph node biopsy in cutaneous head and neck melanoma alter disease outcome?J Surg Oncol. 2006;93:564-570.
36.
KellyJFogartyKRedmondHP. A definitive role for sentinel lymph node mapping with biopsy for cutaneous melanoma of the head and neck. Surgeon. 2009;7:336-339.
37.
ShpitzerTSegalKSchachterJ, et al. Sentinel node guided surgery for melanoma in the head and neck region. Melanoma Res. 2004;14:283-287.
38.
van der PloegAPvan AkkooiACSchmitzPIKoljenovicSVerhoefCEggermontAM. EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria. Eur J Cancer. 2010;46:2414-2421.
39.
MortonDLThompsonJFEssnerR, et al; Multicenter Selective Lymphadenectomy Trial Group. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Ann Surg. 1999;230:453-463.
40.
DotingMHHoekstraHJPlukkerJT, et al. Is sentinel node biopsy beneficial in melanoma patients? A report on 200 patients with cutaneous melanoma. Eur J Surg Oncol. 2002;28:673-678.
41.
FincherTRMcCartyTMFisherTL, et al. Patterns of recurrence after sentinel lymph node biopsy for cutaneous melanoma. Am J Surg. 2003;186:675-681.
42.
EstourgieSHNiewegOEValdes OlmosRAHoefnagelCAKroonBB. Review and evaluation of sentinel node procedures in 250 melanoma patients with a median follow-up of 6 years. Ann Surg Oncol. 2003;10:681-688.
YeeVSThompsonJFMcKinnonJG, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol. 2005;12:429-439.
45.
LeongSPKashani-SabetMDesmondRA, et al. Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up. World J Surg. 2005;29:683-691.
46.
NoweckiZIRutkowskiPNasierowska-GuttmejerARukaW. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Ann Surg Oncol. 2006;13:1655-1663.
47.
CascinelliNBombardieriEBufalinoR, et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol. 2006;24:4464-4471.
48.
KettlewellSMoyesCBrayC, et al. Value of sentinel node status as a prognostic factor in melanoma: prospective observational study. BMJ. 2006;332:1423.
49.
CorriganMACoffeyJCO’SullivanMJFogartyKMRedmondHP. Sentinel lymph node biopsy: is it possible to reduce false negative rates by excluding patients with nodular melanoma?Surgeon. 2006;4:153-157.
50.
EmeryREStevensJSNanceRWCorlessCLVettoJT. Sentinel node staging of primary melanoma by the “10% rule”: pathology and clinical outcomes. Am J Surg. 2007;193:618-622.
51.
Riber-HansenRAbrahamsenHNSorensenBSHamilton-DutoitSJSteinicheT. Quantitative real-time RT-PCR in sentinel lymph nodes from melanoma patients: detection of melanocytic mRNA predicts disease-free survival. APMIS. 2008;116:199-205.
52.
TestoriADe SalvoGLMontescoMC, et al. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). Ann Surg Oncol. 2009;16:2018-2027.
53.
ScogginsCRMartinRCRossMI, et al. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol. 2010;17:709-717.
54.
VeenstraHJWoutersMWKroonBBOlmosRANiewegOE. Less false-negative sentinel node procedures in melanoma patients with experience and proper collaboration. J Surg Oncol. 2011;104:454-457.
55.
de RosaNLymanGHSilberminsD, et al. Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngol Head Neck Surg. 2011;145:375-382.
56.
SabelMSGriffithKSondakVK, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg. 2005;201:37-47.
57.
LeungAMMortonDLOzao-ChoyJ, et al. Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. JAMA Surg. 2013;148:879-884.
58.
ReintgenMMurrayLAkmanK, et al. Evidence for a better nodal staging system for melanoma: the clinical relevance of metastatic disease confined to the sentinel lymph nodes. Ann Surg Oncol. 2013;20:668-674.
59.
GyorkiDEBoyleJOGanlyI, et al. Incidence and location of positive nonsentinel lymph nodes in head and neck melanoma. Eur J Surg Oncol. 2014;40:305-310.
60.
WertzAPDurhamABMalloyKMJohnsonTMBradfordCRMcLeanSA. Total versus superficial parotidectomy for stage III melanoma. Head Neck, 2017;39:1665-1670.
61.
SchadendorfDvan AkkooiACJBerkingC, et al. Melanoma. Lancet. 2018;392:971-984.
62.
KandelMAllayousCDalleS, et al. Update of survival and cost of metastatic melanoma with new drugs: estimations from the MelBase cohort. Eur J Cancer. 2018;105:33-40.
63.
PolkowskaMEkk-CierniakowskiPCzepielewskaEKozlowska-WojciechowskaM. Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patients-real-world data [published online November1, 2018]. Eur J Clin Pharmacol. doi:10.1007/s00228-018-2590-6
64.
SmithMJFSmithHGJoshiK, et al. The impact of effective systemic therapies on surgery for stage IV melanoma. Eur J Cancer. 2018;103:24-31.
65.
CarreauNAPavlickAC. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma [published online October18, 2018]. Future Oncol. doi:10.2217/fon-2018-0607
66.
LongGVHauschildASantinamiM, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813-1823.
67.
EggermontAMChiarion-SileniVGrobJJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845-1855.
68.
EggermontAMMBlankCUMandalaM, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789-1801.
69.
WeberJMandalaMDel VecchioM, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824-1835.
70.
DoepkerMPYamamotoMApplebaumMA, et al. Comparison of single-photon emission computed tomography-computed tomography (SPECT/CT) and conventional planar lymphoscintigraphy for sentinel node localization in patients with cutaneous malignancies. Ann Surg Oncol. 2017;24:355-361.
71.
TrinhBBChapmanBCGleisnerA, et al. SPECT/CT adds distinct lymph node basins and influences radiologic findings and surgical approach for sentinel lymph node biopsy in head and neck melanoma. Ann Surg Oncol. 2018;25:1716-1722.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
